• Mauro Viganò, Alessandra Brocchieri, Angiola Spinetti, Serena Zaltron, Giampaolo Mangia, Floriana Facchetti, Alessandro Fugazza, Francesco Castelli, Massimo Colombo, and Pietro Lampertico.
• Liver Unit, Ospedale San Giuseppe, Università degli Studi di Milano, Milan, Italy.
• J. Clin. Virol. 2014 Dec 1;61(4):600-3.

AbstractTenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor widely used to treat patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. In the HBV monoinfection scenario, only two cases of TDF-associated Fanconi syndrome have been reported thus far. Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV). Though the overall risk of TDF associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular function should be monitored in patients exposed to TDF, especially when other renal risk factors or a history of previous exposure to adefovir dipivoxil (ADV) are present.Copyright © 2014 Elsevier B.V. All rights reserved.

31 keywords...

hide…